Loading stock data…
Artiva Biotherapeutics, Inc. (ARTV)
$11.19+0.06 (+0.58%)
Pre-Market$11.06-0.13 (-1.16%)· Last close Sep 4
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Artiva Biotherapeutics, Inc. in the Healthcare sector is trading at $11.19 with a market capitalization of $547M. Wall Street consensus targets $35.80 (5 analysts), implying a +219.9% move over the next 12 months. The stock is currently 23% below its 52-week high of $14.53, remaining 51.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +219.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.89M↓ | -$24.43M↓ | -$21.93M↑ | -$22.90M↓ | -$22.81M |
| Net Income | -$25.00M↓ | -$23.52M↓ | -$20.77M↑ | -$21.53M↓ | -$21.25M |
Peer Comparison
JNJUNHPFE
Fundamentals
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-s...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$547.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.14%
Volume
Today's trading volume
168,592
Recent News
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. By way of example, Artiva...
Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham
Artiva Biotherapeutics (NASDAQ:ARTV) is prioritizing rheumatoid arthritis (RA) as the lead indication for its non-genetically modified natural killer (NK) cell therapy platform, executives said during a discussion at the Needham Healthcare Conference. Speaking with Needham Senior Biotech Analyst Gil
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update
Artiva Biotherapeutics (NASDAQ:ARTV) used a presentation and fireside chat at TD Cowen’s 46th Annual Healthcare Conference to outline its strategy in “deep B-cell depletion” for autoimmune disease, emphasizing rheumatoid arthritis (RA) as its lead indication and positioning its natural killer (NK) c
AtaiBeckley names Michael Faerm as finance chief
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as the clinical-stage biotechnology company continues to advance its mental health treatment pipeline. According to the company, Faerm brings more than 25...